Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit
Ocugen, a biotechnology company focused on gene and cell therapies, biologics, and vaccines, announced its participation in the 2024 Maxim Healthcare Virtual Summit. Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen, will join a panel discussion on Ocular Drug Development on Tuesday, October 15, 2024, from 11 a.m. to noon EDT.
The panel will explore advancements in vision enhancement, disease modification, and vision restoration. Dr. Musunuri expressed excitement about introducing Ocugen's first-in-class modifier gene therapy platform to investors. The summit, presented by Maxim Group , will feature presentations and discussions with CEOs and key management from various healthcare companies, along with industry panels. The event is exclusive to M-Vest members and will take place from October 15 to October 17, 2024.
Ocugen, un'azienda biotecnologica focalizzata su terapie geniche e cellulari, biologici e vaccini, ha annunciato la sua partecipazione al 2024 Maxim Healthcare Virtual Summit. Il Dr. Shankar Musunuri, Presidente, CEO e Co-fondatore di Ocugen, parteciperà a una discussione di panel sullo Sviluppo dei Farmaci Oculari martedì 15 ottobre 2024, dalle 11:00 a mezzogiorno EDT.
Il panel esplorerà i progressi in miglioramento della vista, modifica delle malattie e ripristino della vista. Il Dr. Musunuri ha espresso entusiasmo per la presentazione della piattaforma di terapia genica modificante di prima classe di Ocugen agli investitori. Il summit, presentato da Maxim Group, includerà presentazioni e discussioni con CEO e membri chiave della gestione di varie aziende del settore sanitario, insieme a panel tematici. L'evento è esclusivo per i membri di M-Vest e si svolgerà dal 15 al 17 ottobre 2024.
Ocugen, una empresa biotecnológica centrada en terapias génicas y celulares, biológicos y vacunas, anunció su participación en el 2024 Maxim Healthcare Virtual Summit. El Dr. Shankar Musunuri, Presidente, CEO y Co-fundador de Ocugen, se unirá a un panel de discusión sobre el Desarrollo de Medicamentos Oculares el martes 15 de octubre de 2024, de 11 a.m. a mediodía EDT.
El panel explorará los avances en mejora de la visión, modificación de enfermedades y restauración de la visión. El Dr. Musunuri expresó su entusiasmo por presentar la plataforma de terapia génica modificadora de primera clase de Ocugen a los inversores. La cumbre, presentada por Maxim Group, incluirá presentaciones y discusiones con CEOs y alta dirección de varias empresas de salud, junto con paneles de la industria. El evento es exclusivo para miembros de M-Vest y se llevará a cabo del 15 al 17 de octubre de 2024.
Ocugen은 유전자 및 세포 치료, 생물학적 제제 및 백신에 중점을 두고 있는 생명공학 회사로, 2024 Maxim Healthcare Virtual Summit에 참여한다고 발표했습니다. Ocugen의 회장, CEO 및 공동 설립자인 Dr. Shankar Musunuri는 2024년 10월 15일 화요일 오전 11시부터 정오 EDT까지 안과 약물 개발에 대한 패널 토론에 참석할 예정입니다.
패널은 시력 향상, 질병 수정 및 시력 복원의 발전을 탐구할 것입니다. Musunuri 박사는 Ocugen의 1급 수정 유전자 치료 플랫폼을 투자자들에게 소개하게 되어 기쁘다고 밝혔습니다. Maxim Group이 주최하는 이번 정상 회담은 다양한 헬스케어 회사의 CEO 및 주요 경영진과의 발표 및 토론을 포함하여 산업 패널도 진행됩니다. 이 행사는 M-Vest 회원 전용이며 2024년 10월 15일부터 17일까지 진행됩니다.
Ocugen, une entreprise de biotechnologie axée sur les thérapies géniques et cellulaires, les biologiques et les vaccins, a annoncé sa participation au 2024 Maxim Healthcare Virtual Summit. Le Dr. Shankar Musunuri, Président, PDG et co-fondateur d'Ocugen, participera à une table ronde sur le Développement des Médicaments Oculaires le mardi 15 octobre 2024, de 11h à midi EDT.
Le panel explorera les avancées en matière de renforcement de la vision, de modification des maladies et de restauration de la vision. Le Dr. Musunuri a exprimé son enthousiasme à l'idée de présenter la plateforme de thérapie génique modifiée de première classe d'Ocugen aux investisseurs. Le sommet, présenté par Maxim Group, comprend des présentations et des discussions avec des PDG et des dirigeants clés de diverses entreprises du secteur de la santé, ainsi que des panels de l'industrie. L'événement est réservé aux membres de M-Vest et se déroulera du 15 au 17 octobre 2024.
Ocugen, ein biotechnologisches Unternehmen, das sich auf Gen- und Zelltherapien, Biologika und Impfstoffe konzentriert, gab seine Teilnahme am 2024 Maxim Healthcare Virtual Summit bekannt. Dr. Shankar Musunuri, Vorsitzender, CEO und Mitbegründer von Ocugen, wird am Dienstag, dem 15. Oktober 2024, von 11 bis 12 Uhr EDT an einer Podiumsdiskussion über die Entwicklung von Augenmedikamenten teilnehmen.
Das Panel wird Fortschritte in der Verbesserung der Sehkraft, der Modifikation von Krankheiten und der Wiederherstellung der Sehkraft untersuchen. Dr. Musunuri äußerte seine Begeisterung darüber, Ocugens erstklassige modifizierende Gentherapie-Plattform Investoren vorzustellen. Der von Maxim Group präsentierte Gipfel wird Präsentationen und Diskussionen mit CEOs und wichtigen Führungskräften verschiedener Gesundheitsunternehmen sowie Branchenpanels umfassen. Die Veranstaltung ist exklusiv für M-Vest-Mitglieder und findet vom 15. bis 17. Oktober 2024 statt.
- None.
- None.
MALVERN, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will join a panel discussion during the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, taking place from Tuesday, October 15 through Thursday, October 17, 2024.
“The Maxim Healthcare Virtual Summit is a new opportunity for Ocugen,” said Dr. Musunuri. “I look forward to introducing our first-in-class modifier gene therapy platform to a notable segment of investors.”
Dr. Musunuri will participate in the Ocular Drug Development panel to discuss advancements and innovations in vision enhancement, disease modification, and vision restoration. The panel includes companies representing the next generation of ocular therapies in mid-to-late-stage development.
Details of the panel are as follows:
Date: Tuesday, October 15, 2024
Time: 11 a.m.—noon EDT
During the Summit, Maxim Senior Analysts will host a wide range of biotechnology, diagnostic, medical device, and healthcare information technology companies in a series of presentations and interactive discussions with CEOs and key management, along with several topical industry panels that promise to be timely and engaging.
This event is exclusively for M-Vest members. To join and reserve your seat, please visit: 2024 Healthcare Virtual Summit | M-Vest.
About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patients’ lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact:
Tiffany Hamilton
Head of Communications
Tiffany.Hamilton@ocugen.com
FAQ
When is Ocugen (OCGN) participating in the 2024 Maxim Healthcare Virtual Summit?
What panel will Ocugen's CEO participate in during the 2024 Maxim Healthcare Virtual Summit?
What technology will Ocugen (OCGN) introduce at the 2024 Maxim Healthcare Virtual Summit?
Who can attend the 2024 Maxim Healthcare Virtual Summit featuring Ocugen (OCGN)?
